Abstract 420P
Background
Cytoreductive surgery (CRS) is a major surgery which consist of extensive tumor debulking, peritonectomy, and multiple visceral resections. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a technique in which chemotherapy is delivered in a heated solution perfused throughout the peritoneal space. In centers performing CRS-HIPEC, a significant survival benefit were observed; However, the rate of post-operative complications remains high. Acute kidney injury is a post-operative complication associated with increased morbidity and mortality and may cause delay in adjuvant chemotherapy or worse, may render the patient ineligible to receive systemic chemotherapy.
Methods
This was a retrospective cohort study, data were collected among adult patients with peritoneal carcinomatosis from colorectal, appendiceal, gastric, gynecologic cancers, and primary peritoneal mesothelioma who underwent CRS-HIPEC between Jan. 2012 and Dec. 2021 at St. Luke’s Medical Center. Data were obtained retrospectively through review of electronic medical records.
Results
A total of 162 patients who met the inclusion criteria were included in the study. Most of the patients were above 60 years old (62; 38%), females (134; 83%), had normal BMI (90; 56%), with ECOG PS 1 (160; 99%) and without comorbidities (84; 52%). Most had gynecologic malignancy (101; 63%) with high tumor grade (92; 58%) and were given with intraperitoneal cisplatin (16l 68%). Elderly patients (OR 2.70 [95% CI 0.88-8.29]; p .043 < .05); with comorbidities (OR 6.52 [95% CI 3.2-13.2]; p .001 < .05); and was given intraperitoneal Cisplatin (OR 3.99 [95% CI 1.99-8.03]; p .001 < 05) were all found to be at a higher risk for developing AKI after CRS-HIPEC.
Conclusions
The investigation noted that the elderly patients with comorbidities were found to have the highest risk of developing post-operative AKI. The most common malignancy was gynecologic cancers with high tumor grade. Cisplatin was the most common intraperitoneal chemotherapy administered and was associated with higher risk of developing acute kidney injury compared to other chemotherapy agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
YO11 - Satisfactory response after Rituximab-Bendamustin in Poor Performance Status Geriatric with Relapsed DLBCL
Presenter: Yasjudan Putra
Session: Poster viewing 06
YO12 - Allogeneic hematopoietic stem cell transplant in a case of acute myeloid leukaemia with end stage renal disease
Presenter: DEVYANI SURANGE
Session: Poster viewing 06
YO13 - Rosai-Dorfman Disease Presenting with Multiple Contiguous Lymphadenopathy: A Case Report
Presenter: Lean Marx Maaño
Session: Poster viewing 06
YO15 - Nasopharyngeal carcinoma in pregnancy: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO16 - New onset SIADH masquerading progression in esthesioneuroblastoma
Presenter: Muthu Manikandan
Session: Poster viewing 06
YO17 - Olfactory Neuroblastoma with Cervical Lymph Node Metastases in a 21- Year old Filipino Woman: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO18 - Challenges in Provision of Patient centered care with a Practical approach in a Resource-limited setting - Steven Johnson Syndrome – Toxic Epidermal Necrolysis (SJS-TEN) overlap related to Phenytoin use and review of logistical challenges related to care provision - a Case Report.
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO19 - Posterior Reversible Encephalopathy Syndrome associated with Pharmacological management of Bowel obstruction at the end of life – a review of two cases separated by 5 years
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO20 - A case of drug-induced large vessel vasculitis with hoarseness as the chief complaint caused by pegfilgrastim during chemotherapy
Presenter: Takuya Sato
Session: Poster viewing 06
YO23 - Neo-adjuvant immunotherapy in operable non-small cell lung carcinoma
Presenter: Padmini S N
Session: Poster viewing 06